This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Japan's Shionogi to raise stake in UK HIV drugmaker ViiV with $2.1bn investment

( January 20, 2026, 02:14 GMT | Official Statement) -- MLex Summary: Japan’s Shionogi has agreed to increase its stake in UK-based HIV drugmaker ViiV Healthcare, investing $2.1 billion to raise its holding from 10 percent to 21.7 percent. The Osaka-based pharmaceutical company said the deal is expected to close by the end of March, subject to competition and foreign direct investment reviews, as well as customary closing conditions. ViiV Healthcare is privately held and was established as a joint venture between GSK and Pfizer, with Shionogi joining later.The statement, in Japanese, is attached....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections